Mereo BioPharma Group plc
("Mereo" or the "Company")
Notification of Director Dealing
London, May 1, 2019 - Mereo BioPharma Group plc (AIM: MPH), a clinical stage UK based biopharmaceutical company focused on rare diseases, received notification that on 29 April 2019, Darcy Nicolle, a person closely associated (PCA) with Wills Hughes-Wilson, Head of Patient Access, purchased 8000 ordinary shares at a price of GBP1.19 per share.
On 30 April 2019, Charles Sermon, General Counsel of Mereo BioPharma, purchased 6456 American Depositary Shares (ADSs) at a price of USD6.00 per share and Richard Jones, Chief Financial Officer of Mereo BioPharma, purchased 1050 American Depositary Shares (ADSs) at a price of USD6.04 per share.
The below announcement and notification is made in accordance with the EU Market Abuse Regulation. The form required under the EU Market Abuse Regulation follows.
1 |
Details of the person discharging managerial responsibilities |
a) |
Name |
Darcy Nicolle |
2 |
Reason for the notification |
a) |
Position/status |
Person closely associated (PCA) with Wills Hughes-Wilson, Head of Patient Access |
b) |
Initial notification/ Amendment |
Initial notification |
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
a) |
Name |
Mereo BioPharma Group plc |
b) |
LEI |
213800U8JQHIJOS5AS09 |
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
a) |
Description of the financial instrument, type of instrument and identification code |
Ordinary Shares |
b) |
Nature of the transaction |
Purchase |
c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
GBP1.19 |
8000 |
|
d) |
Aggregated information: volume, Price |
Aggregated volume: 8000 Aggregated price: GBP1.194 |
e) |
Date of the transaction |
2019-04-29 |
f) |
Place of the transaction |
AIMX |
1 |
Details of the person discharging managerial responsibilities |
a) |
Name |
Charles Sermon |
2 |
Reason for the notification |
a) |
Position/status |
General Counsel |
b) |
Initial notification/ Amendment |
Initial notification |
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
a) |
Name |
Mereo BioPharma Group plc |
b) |
LEI |
213800U8JQHIJOS5AS09 |
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
a) |
Description of the financial instrument, type of instrument and identification code |
MEREO BIOPHARMA GROUP PLC AMERICAN DEPOSITARY SHARES (ADSs) |
b) |
Nature of the transaction |
PURCHASE |
c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
USD6.00 |
6456 |
|
d) |
Aggregated information: volume, Price |
Aggregated volume: 6456 Aggregated price: USD6.00 |
e) |
Date of the transaction |
2019-04-30 |
f) |
Place of the transaction |
XNMS |
1 |
Details of the person discharging managerial responsibilities |
a) |
Name |
Richard Jones |
2 |
Reason for the notification |
a) |
Position/status |
Chief Financial Officer |
b) |
Initial notification/ Amendment |
Initial notification |
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
a) |
Name |
Mereo BioPharma Group plc |
b) |
LEI |
213800U8JQHIJOS5AS09 |
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
a) |
Description of the financial instrument, type of instrument and identification code |
ADS |
b) |
Nature of the transaction |
Purchase |
c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
USD5.94 |
1050 |
|
d) |
Aggregated information: volume, Price |
Aggregated volume: 1050 Aggregated price: USD5.94 |
e) |
Date of the transaction |
2019-04-30 |
f) |
Place of the transaction |
XNMS |